Skip to main content

Advertisement

Table 1 Baseline characteristics for participants of the subcohort and cases

From: Bone markers and cardiovascular risk in type 2 diabetes patients

  Subcohort (n = 218)a Cases (n = 134)
Age (years) 57.9 ± 6.7 58.6 ± 6.9
Women, n (%) 178 (82) 107 (80)
Diabetes duration (years) 5.3 (2.3–10.2) 6.3 (2.6–12.3)
History of CVD, n (%) 30 (14) 40 (30)
Current smoker, n (%) 49 (22) 42 (31)
BMI (kg/m2) 29.4 ± 4.9 30.3 ± 4.9
Systolic blood pressure (mmHg) 141.7 ± 20.8 145.6 ± 23.3
Total cholesterol (mmol/l) 5.2 ± 1.2 5.4 ± 1.1
HDL cholesterol (mmol/l) 1.0 ± 0.3 1.0 ± 0.3
HbA1c (%) 8.1 ± 1.7 8.2 ± 1.7
eGFR (ml/min/1.73 m2) 107.3 ± 24.1 109.1 ± 19.4
Hs-CRP (µg/mmol) 3.3 (1.8–6.5) 3.9 (2.5–6.6)
Osteocalcin (ng/ml) 22.6 (17.1–29.2) 21.7 (17.2–28.7)
Osteopontin (ng/ml) 12.8 (10.1–16.1) 13.5 (11.1–17.4)
Osteonectin (ng/ml) 114.6 (90.0–154.8) 124.4 (95.7–170.4)
Osteoprotegerin (ng/ml) 191.9 ± 55.6 201.0 ± 57.4
Alkaline Phosphatase (ng/ml) 55.8 (46.2–64.2) 56.2 (46.1–70.4)
Sclerostin (ng/ml) 60.3 (47.6–79.2) 60.8 (49.7–76.0)
  1. Data are shown as frequencies (%), mean ± standard deviation or median (interquartile range)
  2. BMI body mass index, HDL high density lipoprotein, eGFR estimated glomerular filtration, Hs-CRP high sensitive C-reactive protein
  3. aThis subcohort included 65 CVD cases